Gastric Cancer Treatment Modalities and Emerging Therapies

Strategic Insights -

A new report published in the journal Epidemiology, Biostatistics and Public Health presents a comprehensive review of gastric cancer treatment modalities and emerging therapies. Researchers at Wenzhou Medical University conducted a systematic review of existing literature and identified promising outcomes for laparoscopic gastrectomy and other minimally invasive surgical approaches. The study also highlights the benefits of Human Epidermal Growth Factor Receptor 2-targeting agents, checkpoint inhibitors, and other immunotherapies, with trastuzumab providing significant benefits when combined with chemotherapy.

Key Takeaways:

  • Gastric cancer is the fourth most prevalent type of cancer and the second leading cause of cancer-related mortality worldwide, with an annual global incidence of 1 million cases and 700,000 deaths.
  • Laparoscopic gastrectomy and other minimally invasive surgical approaches have yielded promising outcomes, either as standalone procedures or in combination with neoadjuvant and adjuvant chemotherapy regimens.
  • Human Epidermal Growth Factor Receptor 2-targeting agents, checkpoint inhibitors, and other immunotherapies have transformed the management of gastric cancer, with trastuzumab providing significant benefits when combined with chemotherapy.
  • Larger prospective or randomized controlled trials should be conducted to confirm current research findings and enhance the efficacy and safety of various therapeutic strategies.
  • A thorough evaluation of existing treatments and novel therapeutic interventions is imperative to guide future research initiatives, formulate effective patient care strategies, and inform policy makers.
  • The study emphasizes the need for further research into the effectiveness and safety of laparoscopic gastrectomy and other minimally invasive surgical approaches.
  • The use of checkpoint inhibitors and other immunotherapies, such as trastuzumab, has shown significant benefits in the treatment of gastric cancer.

Statistics:

  • 1 million: annual global incidence of gastric cancer cases
  • 700,000: annual global deaths from gastric cancer
  • 68 records: number of studies included in the systematic review
  • 20(2): volume and issue number of the journal Epidemiology, Biostatistics and Public Health where the study was published
  • 2282-0930: journal code for Epidemiology, Biostatistics and Public Health
  • 28332: journal article identifier
  • 2025: publication year of the study

Sources:

  • Systematic review of treatment options for gastric cancer and future therapeutic perspectives (Epidemiology, Biostatistics and Public Health, 2025, 20(2))
  • Wenzhou Medical University
  • Epidemiology, Biostatistics and Public Health (journal) - http://www.ebph.it/
  • Milano University Press (publisher) - https://doi-org.sdpl.idm.oclc.org/10.54103/2282-0930/28332